𝔖 Bobbio Scriptorium

✦ LIBER ✦

896 PUBLICATION Survival advantage and modest cost associated with bicalutamide combination therapy compared with castration alone in patients with advanced prostate cancer

Book ID: 118623472
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 162 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)81191-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

897 PUBLICATION Combination therapy with

897 PUBLICATION Combination therapy with bicalutamide 50 mg plus a luteinising hormone-releasing hormone agonist (LHRHa) is cost effective compared with an LHRHa alone in metastatic prostate cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Prostate-specific antigen response to de

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer

✍ Toshiki Kijima; Yasuhisa Fujii; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

PROSTATE-SPECIFIC ANTIGEN RESPONSE TO DE

PROSTATE-SPECIFIC ANTIGEN RESPONSE TO DEFERRED COMBINED ANDROGEN BLOCKADE THERAPY USING BICALUTAMIDE PREDICTS SURVIVAL AFTER SUBSEQUENT OESTROGEN AND DOCETAXEL THERAPIES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

✍ Marc B. Garnick 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB